X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
azetidines - administration & dosage (728) 728
humans (648) 648
male (462) 462
ezetimibe (403) 403
female (394) 394
index medicus (356) 356
anticholesteremic agents - administration & dosage (332) 332
middle aged (313) 313
drug therapy, combination (250) 250
aged (239) 239
azetidines - therapeutic use (220) 220
adult (211) 211
treatment outcome (191) 191
simvastatin - administration & dosage (183) 183
hypercholesterolemia - drug therapy (167) 167
azetidines - adverse effects (161) 161
cholesterol, ldl - blood (161) 161
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (151) 151
pharmacology & pharmacy (146) 146
simvastatin (145) 145
cholesterol (135) 135
administration, oral (132) 132
animals (131) 131
anticholesteremic agents - therapeutic use (128) 128
cardiac & cardiovascular systems (125) 125
azetidines - pharmacology (124) 124
dose-response relationship, drug (124) 124
double-blind method (122) 122
anticoagulants - administration & dosage (101) 101
hypercholesterolemia (101) 101
azetidines - pharmacokinetics (99) 99
safety (95) 95
atorvastatin (94) 94
efficacy (88) 88
medicine, general & internal (88) 88
statins (87) 87
benzylamines (81) 81
risk factors (80) 80
sulfonamides - administration & dosage (80) 80
anticholesteremic agents - adverse effects (79) 79
pyrroles - administration & dosage (76) 76
aged, 80 and over (74) 74
heptanoic acids - administration & dosage (73) 73
peripheral vascular disease (72) 72
prevention (71) 71
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (69) 69
hypercholesterolemia - blood (68) 68
atorvastatin calcium (67) 67
cardiovascular (67) 67
drug combinations (64) 64
drug therapy (64) 64
ximelagatran (64) 64
abridged index medicus (62) 62
adolescent (60) 60
rats (60) 60
time factors (59) 59
double-blind (58) 58
thrombin - antagonists & inhibitors (58) 58
simvastatin - therapeutic use (57) 57
lipids (55) 55
primary hypercholesterolemia (55) 55
atherosclerosis (54) 54
coronary-heart-disease (53) 53
randomized controlled trials as topic (53) 53
drug administration schedule (52) 52
low density lipoproteins (52) 52
therapy (52) 52
cholesterol - blood (51) 51
triglycerides - blood (51) 51
venous thromboembolism (51) 51
anticoagulants - therapeutic use (48) 48
piperidines - administration & dosage (48) 48
young adult (48) 48
antilipemic agents (46) 46
care and treatment (46) 46
clinical trials as topic (46) 46
prospective studies (46) 46
cholesterol, hdl - blood (45) 45
warfarin (45) 45
pharmacokinetics (44) 44
statin therapy (44) 44
benzylamines - administration & dosage (43) 43
hypolipidemic agents - administration & dosage (43) 43
cholesterol absorption inhibitor (42) 42
cholesterol, ldl - drug effects (42) 42
hematology (42) 42
rats, sprague-dawley (41) 41
analysis (40) 40
hyperlipidemias - drug therapy (40) 40
melagatran (40) 40
statin (40) 40
risk (39) 39
simvastatin - adverse effects (39) 39
anticoagulants - adverse effects (38) 38
anticholesteremic agents - pharmacology (37) 37
coronary heart disease (37) 37
lipids - blood (37) 37
mice (37) 37
follow-up studies (36) 36
internal medicine (36) 36
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (662) 662
German (29) 29
French (7) 7
Japanese (7) 7
Spanish (7) 7
Hungarian (6) 6
Russian (5) 5
Czech (4) 4
Danish (3) 3
Italian (3) 3
Turkish (2) 2
Chinese (1) 1
Dutch (1) 1
Finnish (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2014, Volume 371, Issue 20, pp. 1867 - 1876
Journal Article
JAMA, ISSN 0098-7484, 02/2005, Volume 293, Issue 6, pp. 681 - 689
CONTEXT Ximelagatran, an oral direct thrombin inhibitor with a rapid onset of action and predictable antithrombotic effect, has the potential to be a simple... 
ORAL XIMELAGATRAN | ENOXAPARIN | MEDICINE, GENERAL & INTERNAL | KNEE REPLACEMENT | THERAPY | VENOUS THROMBOEMBOLISM | MELAGATRAN | INTRAVENOUS UNFRACTIONATED HEPARIN | ABSORPTION | INHIBITOR XIMELAGATRAN | SECONDARY PREVENTION | Prodrugs - administration & dosage | Recurrence | Anticoagulants - administration & dosage | Humans | Middle Aged | Male | Venous Thrombosis - complications | Heparin, Low-Molecular-Weight - therapeutic use | Warfarin - administration & dosage | Warfarin - therapeutic use | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | Pulmonary Embolism - complications | Double-Blind Method | Venous Thrombosis - drug therapy | Venous Thrombosis - mortality | Anticoagulants - therapeutic use | Treatment Outcome | Azetidines - administration & dosage | Azetidines - therapeutic use | Benzylamines | Aged | Prodrugs - therapeutic use | Alanine Transaminase - metabolism | Heparin, Low-Molecular-Weight - administration & dosage | Clinical trials | Cardiac arrhythmia | Thrombolytic drugs | Medical treatment | Blood clots | Low-Molecular-Weight/administration & dosage/therapeutic use | Anticoagulants/administration & dosage/therapeutic use | Pulmonary Embolism/complications | Drug Therapy | MEDICIN OCH HÄLSOVETENSKAP | Alanine Transaminase/metabolism | Warfarin/administration & dosage/therapeutic use | 80 and over | Azetidines/administration & dosage/therapeutic use | Combination | Prodrugs/administration & dosage/therapeutic use | Venous Thrombosis/complications/drug therapy/mortality | Heparin | MEDICAL AND HEALTH SCIENCES
Journal Article
Journal Article
Immunity, ISSN 1074-7613, 03/2016, Volume 44, Issue 3, pp. 609 - 621
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 08/2015, Volume 100, Issue 8, pp. 3140 - 3148
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9784, pp. 2181 - 2192
Summary Background Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary... 
Internal Medicine | UNITED-KINGDOM HEART | DESIGN | METAANALYSIS | REQUIRING PROLONGED OBSERVATION | EFFICACY | CARDIOVASCULAR EVENTS | SAFETY | HEMODIALYSIS | OUTCOMES | UMCG Approved | PARTICIPANTS | MEDICINE, GENERAL & INTERNAL | Confidence Intervals | Simvastatin - adverse effects | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Ezetimibe | Renal Dialysis - methods | Male | Reference Values | Cholesterol, LDL - analysis | Kidney Function Tests | Renal Insufficiency, Chronic - drug therapy | Dose-Response Relationship, Drug | Renal Insufficiency, Chronic - therapy | Renal Dialysis - mortality | Time Factors | Renal Insufficiency, Chronic - mortality | Adult | Female | Renal Insufficiency, Chronic - diagnosis | Drug Therapy, Combination | Severity of Illness Index | Hypolipidemic Agents - adverse effects | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Simvastatin - administration & dosage | Cholesterol, LDL - drug effects | Treatment Outcome | Azetidines - administration & dosage | Hypolipidemic Agents - administration & dosage | Survival Analysis | Aged | Simvastatin | Low density lipoproteins | Physiological aspects | Drug therapy, Combination | Research | Kidney diseases | Diagnosis | Drug therapy | Health aspects | Studies | Heart failure | Cardiac arrhythmia | Medical imaging | Hospitals | Compliance | Cardiovascular disease | Blood pressure | Family medical history | Cholesterol | Cancer | Mortality | myocardial infarction | cholesterol | councils | Dialysis | medical research | stroke | Kidney | Fast track | Pharmaceutical Sciences | Basic Medicine | PHARMACY | Medical and Health Sciences | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper | FARMACI | Farmaceutiska vetenskaper
Journal Article